Kala Bio Inc (KALA) Stock Price, Quote & News - Mboum

Company Profile

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent co...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

Beginer_Trading Jun. 26 at 10:49 AM

$KALA what is the filing yesterday

0 · Reply

Momikhan Jun. 25 at 7:45 PM

$KALA This stock is scam stay away from this. They don't have any revenue and product just bunch of people making fake pump to loot you !

2 · Reply

Surfix Jun. 24 at 2:54 PM

$KALA cup and handle

2 · Reply

Hassan77 Jun. 22 at 8:40 PM

$KALA Should be in the clear for bullish continuation tomorrow.

1 · Reply

Hassan77 Jun. 22 at 6:34 PM

$KALA Go green and lets break $4

0 · Reply

ThotBroker Jun. 22 at 4:09 PM

0 · Reply

Hassan77 Jun. 22 at 12:57 PM

$KALA In with 1100 shares. Looking for a solid move today.

0 · Reply

Hassan77 Jun. 22 at 12:52 PM

$AZTR Got out this morning @.23 they are playing games here and feel like they are going to take it back under .20 today..Going to move to $KALA

0 · Reply

StockScanners Jun. 19 at 4:10 AM

$KALA 3.36 is the level that has my attention. If price can continue holding above that area, it would suggest the current trend remains intact and the chart continues building from a position of strength. That's the level I'd want to see respected.

0 · Reply

topstockalerts Jun. 19 at 12:48 AM

$KALA this is one of those setups you don’t want to ignore

0 · Reply

Latest News on KALA

KALA BIO Registration statement: Registration filing

Jun 12, 2026, 8:00 AM EDT - 17 days ago

KALA BIO Registration statement: Registration filing

KALA BIO Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 6 weeks ago

KALA BIO Quarterly report: Q1 2026

Kala Bio falls -21.7%

2026-05-12T17:59:22.000Z - 6 weeks ago

Kala Bio falls -21.7%

KALA BIO Announces Reverse Stock Split

May 7, 2026, 9:00 AM EDT - 7 weeks ago

KALA BIO Announces Reverse Stock Split

KALA BIO Registration statement: Registration filing

May 7, 2026, 8:00 AM EDT - 7 weeks ago

KALA BIO Registration statement: Registration filing

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Apr 21, 2026, 7:00 AM EDT - 2 months ago

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

KALA BIO Annual report: Q4 2025

Apr 15, 2026, 7:00 AM EDT - 2 months ago

KALA BIO Annual report: Q4 2025

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

Apr 1, 2026, 6:45 AM EDT - 3 months ago

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Mar 30, 2026, 8:45 AM EDT - 3 months ago

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 9:00 AM EDT - 3 months ago

Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 8:15 AM EDT - 3 months ago

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Mar 11, 2026, 11:18 AM EDT - 3 months ago

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Mar 11, 2026, 6:30 AM EDT - 3 months ago

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

Mar 4, 2026, 6:30 AM EST - 4 months ago

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

KALA BIO Registration statement: Registration Filing

Feb 10, 2026, 7:00 AM EST - 4 months ago

KALA BIO Registration statement: Registration Filing

KALA BIO Transcript: AGM 2026

Jan 30, 2026, 11:00 AM EST - 5 months ago

KALA BIO Transcript: AGM 2026

KALA BIO Proxy statement: Proxy Filing

Jan 26, 2026, 7:00 AM EST - 5 months ago

KALA BIO Proxy statement: Proxy Filing

KALA BIO Proxy statement: Proxy Filing

Jan 6, 2026, 7:00 AM EST - 6 months ago

KALA BIO Proxy statement: Proxy Filing

KALA BIO Settles Approximately $10.6 million of Debt

Jan 5, 2026, 4:10 PM EST - 6 months ago

KALA BIO Settles Approximately $10.6 million of Debt

KALA BIO Proxy statement: Proxy Filing

Dec 30, 2025, 7:00 AM EST - 6 months ago

KALA BIO Proxy statement: Proxy Filing

KALA BIO Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 6 months ago

KALA BIO Proxy statement: Proxy Filing

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025, 10:45 AM EST - 7 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

KALA BIO Quarterly report: Q3 2025

Nov 19, 2025, 4:00 PM EST - 7 months ago

KALA BIO Quarterly report: Q3 2025

KALA BIO Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 2:00 PM EDT - 10 months ago

KALA BIO Transcript: H.C. Wainwright 27th Annual Global Investment Conference

KALA BIO Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 1:00 PM EDT - 11 months ago

KALA BIO Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 8, 2025, 8:00 AM EDT - 11 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO Quarterly report: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 11 months ago

KALA BIO Quarterly report: Q2 2025

KALA BIO Earnings release: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 11 months ago

KALA BIO Earnings release: Q2 2025

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 8:00 AM EDT - 11 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO Transcript: Status Update

Jul 16, 2025, 4:00 PM EDT - 1 year ago

KALA BIO Transcript: Status Update

KALA BIO Slides: Status Update

Jul 16, 2025, 4:00 PM EDT - 1 year ago

KALA BIO Slides: Status Update

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Jul 9, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 1:25 PM EDT - 1 year ago

KALA BIO Transcript: Jefferies Global Healthcare Conference 2025

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 1 year ago

KALA BIO to Present at Jefferies Global Healthcare Conference

KALA BIO Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Quarterly report: Q1 2025

KALA BIO Earnings release: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q1 2025

KALA BIO Annual report: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Annual report: Q4 2024

KALA BIO Earnings release: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q4 2024

KALA BIO Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

KALA BIO Transcript: TD Cowen 45th Annual Healthcare Conference

KALA BIO Announces Chief Executive Officer Transition

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

KALA BIO Registration statement: Registration Filing

Jan 24, 2025, 7:00 AM EST - 1 year ago

KALA BIO Registration statement: Registration Filing

KALA BIO Announces $10,750,000 Private Placement

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

KALA BIO Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 11:30 AM EST - 1 year ago

KALA BIO Transcript: Piper Sandler 36th Annual Healthcare Conference

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

KALA BIO Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

KALA BIO Quarterly report: Q3 2024

KALA BIO Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

KALA BIO Earnings release: Q3 2024

KALA BIO Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 15, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

KALA BIO Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Quarterly report: Q2 2024

KALA BIO Earnings release: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Earnings release: Q2 2024

KALA BIO Registration statement: Registration Filing

Jul 25, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Registration statement: Registration Filing

KALA BIO Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

KALA BIO Transcript: Jefferies 2024 Global Healthcare Conference

KALA BIO Proxy statement: Proxy Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:05 PM EDT - 2 years ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

KALA BIO Quarterly report: Q1 2024

KALA BIO Earnings release: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

KALA BIO Earnings release: Q1 2024

KALA BIO Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

KALA BIO Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

KALA BIO Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

KALA BIO Earnings release: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Earnings release: Q4 2023

KALA BIO Annual report: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Annual report: Q4 2023

KALA BIO Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 12:50 PM EST - 2 years ago

KALA BIO Transcript: TD Cowen 44th Annual Health Care Conference 2024

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

KALA BIO Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Feb 13, 2024, 12:00 PM EST - 2 years ago

KALA BIO Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

KALA BIO Quarterly report: Q3 2023

KALA BIO Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

KALA BIO Earnings release: Q3 2023

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 3 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 4, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO Quarterly report: Q2 2023

Aug 4, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Quarterly report: Q2 2023

KALA BIO Earnings release: Q2 2023

Aug 4, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Earnings release: Q2 2023

KALA BIO to Participate in Upcoming Investor Conferences in August

Aug 2, 2023, 4:01 PM EDT - 3 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 19, 2023, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

KALA BIO Proxy statement: Proxy Filing

Jun 1, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

KALA BIO Proxy statement: Proxy Filing

May 11, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO Registration statement: Registration Filing

May 9, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Registration statement: Registration Filing

KALA BIO Quarterly report: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Quarterly report: Q1 2023

KALA BIO Earnings release: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Earnings release: Q1 2023

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

KALA BIO Proxy statement: Proxy Filing

Mar 13, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

KALA BIO Annual report: Q4 2022

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Annual report: Q4 2022

KALA BIO Earnings release: Q4 2022

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Earnings release: Q4 2022

KALA BIO Registration statement: Registration Filing

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Registration statement: Registration Filing

KALA BIO Registration statement: Registration Filing

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Registration statement: Registration Filing

KALA BIO Proxy statement: Proxy Filing

Mar 1, 2023, 7:00 AM EST - 3 years ago

KALA BIO Proxy statement: Proxy Filing

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

KALA BIO Quarterly report: Q3 2022

Nov 8, 2022, 8:30 AM EST - 3 years ago

KALA BIO Quarterly report: Q3 2022

KALA BIO Earnings release: Q3 2022

Nov 8, 2022, 8:30 AM EST - 3 years ago

KALA BIO Earnings release: Q3 2022

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Kala Pharmaceuticals Announces Reverse Stock Split

Oct 20, 2022, 7:30 AM EDT - 4 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

KALA BIO Proxy statement: Proxy Filing

Sep 9, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

KALA BIO Proxy statement: Proxy Filing

Aug 30, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 19, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 18, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

KALA BIO Earnings Call Transcript: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Earnings Call Transcript: Q2 2022

KALA BIO Quarterly report: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Quarterly report: Q2 2022

KALA BIO Earnings release: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Earnings release: Q2 2022

KALA BIO Slides: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Slides: Q2 2022

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Aug 4, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jul 11, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

KALA BIO Proxy statement: Proxy Filing

May 31, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 23, 2022, 12:01 AM EDT - 4 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

KALA BIO Earnings Call Transcript: Q1 2022

May 16, 2022, 9:33 AM EDT - 4 years ago

KALA BIO Earnings Call Transcript: Q1 2022

KALA BIO Quarterly report: Q1 2022

May 16, 2022, 9:33 AM EDT - 4 years ago

KALA BIO Quarterly report: Q1 2022

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 16, 2022, 7:00 AM EDT - 4 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

Beginer_Trading Jun. 26 at 10:49 AM

$KALA what is the filing yesterday

0 · Reply

Momikhan Jun. 25 at 7:45 PM

$KALA This stock is scam stay away from this. They don't have any revenue and product just bunch of people making fake pump to loot you !

2 · Reply

Surfix Jun. 24 at 2:54 PM

$KALA cup and handle

2 · Reply

Hassan77 Jun. 22 at 8:40 PM

$KALA Should be in the clear for bullish continuation tomorrow.

1 · Reply

Hassan77 Jun. 22 at 6:34 PM

$KALA Go green and lets break $4

0 · Reply

ThotBroker Jun. 22 at 4:09 PM

0 · Reply

Hassan77 Jun. 22 at 12:57 PM

$KALA In with 1100 shares. Looking for a solid move today.

0 · Reply

Hassan77 Jun. 22 at 12:52 PM

$AZTR Got out this morning @.23 they are playing games here and feel like they are going to take it back under .20 today..Going to move to $KALA

0 · Reply

StockScanners Jun. 19 at 4:10 AM

$KALA 3.36 is the level that has my attention. If price can continue holding above that area, it would suggest the current trend remains intact and the chart continues building from a position of strength. That's the level I'd want to see respected.

0 · Reply

topstockalerts Jun. 19 at 12:48 AM

$KALA this is one of those setups you don’t want to ignore

0 · Reply

stockwitsuser2449 Jun. 18 at 11:23 PM

0 · Reply

xpro123 Jun. 18 at 10:24 PM

$KALA I want more

0 · Reply

topstockalerts Jun. 18 at 9:30 PM

$KALA the move feels much more organized than random.

0 · Reply

TakeWhatYouGet Jun. 18 at 8:10 PM

$KALA Told ya and still Not finished

0 · Reply

jv39 Jun. 18 at 8:08 PM

$KALA Wow that was some serious candle!!

0 · Reply

RedDogSailor Jun. 18 at 7:30 PM

$KALA Holding for $6-7 minimum.

0 · Reply

FSMuffins Jun. 18 at 5:38 PM

$KALA easy money for downside

0 · Reply

Stock_Catcher Jun. 18 at 5:25 PM

$BFLY new high of day too, $BESS $APLM $MDCX $KALA Thin setups im watching

0 · Reply

jv39 Jun. 18 at 5:04 PM

$KALA Going to $6 at least

0 · Reply

MadStockAlerts1 Jun. 18 at 6:42 AM

$KALA called at $2.63, ran straight to $3.41 for a clean +30%. 📈 Still holding gains at $2.85, up +8% from the alert. While Wall Street kept this one quiet, we shared it plain. Let's keep spotting these together. 🤝

0 · Reply

MadStockAlerts1 Jun. 18 at 5:43 AM

$KALA called at $2.63, ran straight to $3.41 for a clean +30%. 📈 Still holding gains at $2.85, up +8% from the alert. Let's keep spotting these together. 🤝

0 · Reply

7traderja Jun. 17 at 12:01 PM

$KALA target price here?

2 · Reply